Drug-target residence time and its implications for lead optimization
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromolecules by low-molecular-mass drugs. The binding of drugs to their macromolecular targets is therefore seen as paramount for pharmacological activity. In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC(50) or K(d). This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex. We describe the potential advantages of long residence time in terms of duration of pharmacological effect and target selectivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The translation between slow inhibitor binding kinetics and sustained pharmacodynamic modulation has been studied for a numberoftarget classes (58).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [58]
In the citing paper
“Furthermore, the targets of infectious diseases usually have high replication rates, while covalent inhibitors tend to have long residence times making them less effective in this area [128].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [128]
In the citing paper
“Furthermore, longer residence times of drugs with their targets, as a result of slower off-rates, is a useful mechanism to extend in-vivo efficacy (59–61).”
From A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit (2026) · cites this paper as [59]
Citations
Cites
Catalysis in chemistry and enzymology
Jencks, W. P. (1969) · Medical Entomology and Zoology · Cited by 3,217
Structure and Mechanism in Protein Science
Fersht, A. (1998) · Cited by 1,882
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Self-citationLiang, J., Woodward, C., & Edelsbrunner, H. (1998) · Protein Science · doi:10.1002/pro.5560070905 · Cited by 1,057
Enzymes: a practical introduction to structure, mechanism, and data analysis
(2001) · Choice Reviews Online · doi:10.5860/choice.38-3881 · Cited by 1,056
Optical biosensors in drug discovery
Cooper, M. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd838 · Cited by 1,015
Oppenheimer, N. J., & James, T. L. (1989) · Academic Press eBooks · Cited by 820
Rusnak, D. W., Lackey, K. E., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., et al. (2001) · PubMed · Cited by 728
Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis
Copeland, R. A. (2000) · Wiley eBooks · doi:10.1002/0471220639 · Cited by 726
Self-citation
Cited by
Items 101–200 of 1,003
Protein-Imprinted Polymers: The Shape of Things to Come?
Culver, H. R., & Peppas, N. A. (2017) · Chemistry of Materials · doi:10.1021/acs.chemmater.7b01936 · Cited by 165
Dierynck, I., Wit, M. D., Gustin, E. M., Keuleers, I., Vandersmissen, J., Hallenberger, S., & Hertogs, K. (2007) · Journal of Virology · doi:10.1128/jvi.01184-07 · Cited by 157
Simard, J. R., Getlik, M., Grütter, C., Pawar, V. T., Wulfert, S., Rabiller, M., & Rauh, D. (2009) · Journal of the American Chemical Society · doi:10.1021/ja902010p · Cited by 168
Rai, G., Brimacombe, K. R., Mott, B. T., Urban, D. J., Hu, X., Yang, S.-M., Lee, T. D., Cheff, D. M., Kouznetsova, J., Benavides, G. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00941 · Cited by 152
Guerlavais, V., Sawyer, T. K., Carvajal, L., Chang, Y. S., Graves, B., Ren, J.-G., Sutton, D., Olson, K. A., Packman, K., Darlak, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00623 · Cited by 136
Kinetics of protein-ligand unbinding via smoothed potential molecular dynamics simulations
Mollica, L., Decherchi, S., Zia, S. R., Gaspari, R., Cavalli, A., & Rocchia, W. (2015) · Scientific Reports · doi:10.1038/srep11539 · Cited by 155
Nicolas, G. P., Mansi, R., McDougall, L., Kaufmann, J., Bouterfa, H., Wild, D., & Fani, M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191684 · Cited by 149
Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
Wang, J., Fei, K., Jing, H., Wu, Z., Wu, W., Zhou, S., Ni, H., Chen, B., Xiong, Y., Liu, Y., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1654303 · Cited by 149
Cavalli, A., Spitaleri, A., Saladino, G., & Gervasio, F. L. (2015) · Accounts of Chemical Research · doi:10.1021/ar500356n · Cited by 149
Basavapathruni, A., Jin, L., Daigle, S. R., Majer, C. R., Therkelsen, C. A., Wigle, T. J., Kuntz, K. W., Chesworth, R., Pollock, R. M., Scott, M. P., et al. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12050 · Cited by 147
Self-citationKolář, M. H., Hostaš, J., & Hobza, P. (2014) · Physical Chemistry Chemical Physics · doi:10.1039/c3cp55188a · Cited by 154
Translating slow-binding inhibition kinetics into cellular and in vivo effects
Walkup, G. K., You, Z., Ross, P. L., Allen, E. K. H., Daryaee, F., Hale, M. R., O’Donnell, J. C., Ehmann, D. E., Schuck, V., Buurman, E. T., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1796 · Cited by 160
Domon, Y., Arakawa, N., Inoue, T., Matsuda, F., Takahashi, M., Yamamura, N., Kai, K., & Kitano, Y. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.247551 · Cited by 156
Advances in free-energy-based simulations of protein folding and ligand binding
Pérez, A., Morrone, J. A., Simmerling, C. L., & Dill, K. A. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2015.12.002 · Cited by 155
Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc
Getlik, M., Grütter, C., Simard, J. R., Klüter, S., Rabiller, M., Rode, H. B., Robubi, A., & Rauh, D. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9002928 · Cited by 159
Mechanism and In Vitro Pharmacology of TAK1 Inhibition by (5Z)-7-Oxozeaenol
Wu, J., Powell, F., Larsen, N., Lai, Z., Byth, K., Read, J. A., Gu, R.-F., Roth, M., Toader, D., Saeh, J. C., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb3005897 · Cited by 145
Inhibitor Mediated Protein Degradation
Long, M. J. C., Gollapalli, D. R., & Hedstrom, L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.04.008 · Cited by 133
Lysine-Targeted Inhibitors and Chemoproteomic Probes
Cuesta, A., & Taunton, J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044805 · Cited by 129
Targeting enzyme inhibitors in drug discovery
Copeland, R. A., Harpel, M. R., & Tummino, P. J. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.7.967 · Cited by 152
Self-citationNew approaches for computing ligand–receptor binding kinetics
Bruce, N. J., Ganotra, G. K., Kokh, D. B., Sadiq, S. K., & Wade, R. C. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2017.10.001 · Cited by 146
Effects of target binding kinetics onin vivodrug efficacy: koff, konand rebinding
Vauquelin, G. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13504 · Cited by 154
Glycomimetics for the inhibition and modulation of lectins
Leusmann, S., Ménová, P., Shanina, E., Titz, A., & Rademacher, C. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00954d · Cited by 141
Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
Pádua, R. A. P., Sun, Y., Marko, I., Pitsawong, W., Stiller, J. B., Otten, R., & Kern, D. (2018) · Nature Communications · doi:10.1038/s41467-018-06814-w · Cited by 133
Structure–kinetic relationship study of CDK8/CycC specific compounds
Schneider, E. V., Böttcher, J., Huber, R., Maskos, K., & Neumann, L. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305378110 · Cited by 131
Molecular Pharmacology of δ-Opioid Receptors
Gendron, L., Cahill, C. M., von Zastrow, M., Schiller, P. W., & Piñeyro, G. (2016) · Pharmacological Reviews · doi:10.1124/pr.114.008979 · Cited by 149
A new screening assay for allosteric inhibitors of cSrc
Simard, J. R., Klüter, S., Grütter, C., Getlik, M., Rabiller, M., Rode, H. B., & Rauh, D. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.162 · Cited by 144
Ligand–receptor interaction platforms and their applications for drug discovery
Fang, Y. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.715631 · Cited by 124
Strategies for the Development of Glycomimetic Drug Candidates
Hevey, R. (2019) · Pharmaceuticals · doi:10.3390/ph12020055 · Cited by 138
Gavaldà, A., Miralpeix, M., Ramos, I., Otal, R., Carreño, C., Viñals, M., Domènech, T., Carcasona, C., Reyes, B., Vilella, D., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.151639 · Cited by 129
Yoshikawa, M., Saitoh, M., Katoh, T., Seki, T., Bigi-Botterill, S. V., Shimizu, Y., Ishii, T., Okai, T., Kuno, M., Hattori, H., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01647 · Cited by 131
Lotz, S. D., & Dickson, A. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08572 · Cited by 126
Novel Computational Approach to Predict Off-Target Interactions for Small Molecules
Rao, M. S., Gupta, R., Liguori, M. J., Hu, M., Huang, X., Mantena, S. R., Mittelstadt, S. W., Blomme, E. A. G., & Van Vleet, T. R. (2019) · Frontiers in Big Data · doi:10.3389/fdata.2019.00025 · Cited by 118
Mons, E., Roet, S., Kim, R. Q., & Mulder, M. P. C. (2022) · Current Protocols · doi:10.1002/cpz1.419 · Cited by 138
Kinetics from Metadynamics: Principles, Applications, and Outlook
Ray, D., & Parrinello, M. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00660 · Cited by 134
Water Network Perturbation in Ligand Binding: Adenosine A2AAntagonists as a Case Study
Bortolato, A., Tehan, B. G., Bodnarchuk, M. S., Essex, J. W., & Mason, J. S. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci4001458 · Cited by 119
Targeting Conformational Plasticity of Protein Kinases
Tong, M., & Seeliger, M. A. (2014) · ACS Chemical Biology · doi:10.1021/cb500870a · Cited by 127
Binding kinetics of ligands acting at GPCRs
Sykes, D. A., Stoddart, L. A., Kilpatrick, L. E., & Hill, S. J. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.01.018 · Cited by 138
Hennessy, E. J., Adam, A., Aquila, B. M., Castriotta, L., Cook, D. J., Hattersley, M. M., Hird, A. W., Huntington, C., Kamhi, V. M., Laing, N. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401075x · Cited by 126
Copeland, R. A., Basavapathruni, A., Moyer, M. P., & Scott, M. P. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.05.029 · Cited by 119
Self-citationIn vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant
de Witte, W. E. A., Danhof, M., van der Graaf, P. H., & de Lange, E. C. M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.06.008 · Cited by 121
Quantifying CDK inhibitor selectivity in live cells
Wells, C. I., Vasta, J. D., Corona, C. R., Wilkinson, J., Zimprich, C. A., Ingold, M. R., Pickett, J. E., Drewry, D. H., Pugh, K. M., Schwinn, M. K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16559-0 · Cited by 114
Johnson, E. F., Stewart, K. D., Woods, K. W., Giranda, V. L., & Luo, Y. (2007) · Biochemistry · doi:10.1021/bi7008745 · Cited by 118
NanoBRET Approaches to Study Ligand Binding to GPCRs and RTKs
Stoddart, L. A., Kilpatrick, L. E., & Hill, S. J. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.006 · Cited by 118
Spassov, D. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137124 · Cited by 137
Experiences in Fragment-Based Lead Discovery
Hubbard, R. E., & Murray, J. B. (2011) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-381274-2.00020-0 · Cited by 116
Survey of the year 2006 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2007) · Journal of Molecular Recognition · doi:10.1002/jmr.862 · Cited by 131
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach
Engel, J., Richters, A., Getlik, M., Tomassi, S., Keul, M., Termathe, M., Lategahn, J., Becker, C., Mayer‐Wrangowski, S. C., Grütter, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01082 · Cited by 123
Lin, H., Yang, J., Wang, D., Hao, G., Dong, J., Wang, Y., Yang, W., Wu, J., Zhan, C., & Yang, G. (2019) · FEBS Journal · doi:10.1111/febs.14747 · Cited by 115
Decherchi, S., Berteotti, A., Bottegoni, G., Rocchia, W., & Cavalli, A. (2015) · Nature Communications · doi:10.1038/ncomms7155 · Cited by 120
Okaniwa, M., Hirose, M., Arita, T., Yabuki, M., Nakamura, A., Takagi, T., Kawamoto, T., Uchiyama, N., Sumita, A., Tsutsumi, S., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400778d · Cited by 108
Lu, H., England, K., Ende, C. W. A., Truglio, J. J., Luckner, S. R., Reddy, B. G., Marlenee, N. L., Knudson, S. E., Knudson, D. L., Bowen, R. A., et al. (2009) · ACS Chemical Biology · doi:10.1021/cb800306y · Cited by 113
Lee, K. S. S., Liu, J.-Y., Wagner, K. M., Pakhomova, S., Dong, H., Morisseau, C., Fu, S. H., Yang, J., Wang, P., Ulu, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500694p · Cited by 103
Bernetti, M., Cavalli, A., & Mollica, L. (2017) · MedChemComm · doi:10.1039/c6md00581k · Cited by 120
Liu, Q., Kirubakaran, S., Hur, W., Niepel, M., Westover, K., Thoreen, C. C., Wang, J., Ni, J., Patricelli, M. P., Vogel, K., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.304485 · Cited by 107
DeepBindRG: a deep learning based method for estimating effective protein–ligand affinity
Zhang, H., Liao, L., Saravanan, K. M., Yin, P., & Wei, Y. (2019) · PeerJ · doi:10.7717/peerj.7362 · Cited by 107
Biolayer interferometry and its applications in drug discovery and development
Jug, A., Bratkovič, T., & Ilaš, J. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117741 · Cited by 107
Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease
Shrestha, L., Bolaender, A., J. Patel, H., & Taldone, T. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160413141911 · Cited by 104
Fabre, B., Ramos, A., & de Pascual‐Teresa, B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500505f · Cited by 111
Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers
Wagner, F. F., Zhang, Y.-L., Fass, D. M., Joseph, N., Gale, J. P., Weïwer, M., McCarren, P., Fisher, S. L., Kaya, T., Zhao, W.-N., et al. (2015) · Chemical Science · doi:10.1039/c4sc02130d · Cited by 104
An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently
Viaud, J., & Peterson, J. R. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0102 · Cited by 104
Hit Generation in TB Drug Discovery: From Genome to Granuloma
Yuan, T., & Sampson, N. S. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00602 · Cited by 110
Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1
Ryan, K., Bolaños, B., Smith, M. L., Palde, P. B., Cuenca, P. D., VanArsdale, T. L., Niessen, S., Zhang, L., Behenna, D. C., Ornelas, M. A., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.016573 · Cited by 112
Gabrielsson, J., Dolgos, H., Gillberg, P., Bredberg, U., Benthem, B., & Duker, G. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.12.011 · Cited by 104
Mollica, L., Théret, I., Antoine, M., Perron‐Sierra, F., Charton, Y., Fourquez, J., Wierzbicki, M., Boutin, J. A., Ferry, G., Decherchi, S., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00632 · Cited by 104
Trk kinase inhibitors as new treatments for cancer and pain
Wang, T., Yu, D., & Lamb, M. L. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902721261 · Cited by 104
Inhibiting the HIV Integration Process: Past, Present, and the Future
Santo, R. D. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400674a · Cited by 112
Sun, H., Li, Y., Tian, S., Wang, J., & Hou, T. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003729 · Cited by 99
Single-Molecule Detection and Mismatch Discrimination of Unlabeled DNA Targets
Gunnarsson, A., Jönsson, P., Marie, R., Tegenfeldt, J. O., & Höök, F. (2007) · Nano Letters · doi:10.1021/nl072401j · Cited by 112
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
Pavan, M., Menin, S., Bassani, D., Sturlese, M., & Moro, S. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00995 · Cited by 107
Light-controlled modulation of gene expression by chemical optoepigenetic probes
Reis, S. A., Ghosh, B., Hendricks, J. A., Szantai‐Kis, D. M., Toerk, L., Ross, K. N., Lamb, J., Read-Button, W., Zheng, B., Wang, H., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2042 · Cited by 106
Votapka, L. W., Jagger, B. R., Heyneman, A. L., & Amaro, R. E. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b09388 · Cited by 96
A look at ligand binding thermodynamics in drug discovery
Claveria‐Gimeno, R., Vega, S., Abián, O., & Velázquez‐Campoy, A. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1297418 · Cited by 105
Huo, T., Zhao, X., Cheng, Z., Wei, J., Zhu, M., Dou, X., & Jiao, N. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.021 · Cited by 110
Naik, M., Humnabadkar, V., Tantry, S. J., Panda, M., Narayan, A., Guptha, S., Panduga, V., Manjrekar, P., Jena, L. K., Koushik, K., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5005978 · Cited by 98
Free energy landscape for the binding process of Huperzine A to acetylcholinesterase
Bai, F., Xu, Y., Chen, J., Liu, Q., Gu, J., Wang, X., Ma, J., Li, H., Onuchic, J. N., & Jiang, H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301814110 · Cited by 97
Multisecond ligand dissociation dynamics from atomistic simulations
Wolf, S., Lickert, B., Bray, S., & Stock, G. (2020) · Nature Communications · doi:10.1038/s41467-020-16655-1 · Cited by 85
Tautermann, C. S., Kiechle, T., Seeliger, D., Diehl, S., Wex, E., Banholzer, R., Gantner, F., Pieper, M. P., & Casarosa, P. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401219y · Cited by 94
Rebinding: or why drugs may act longerin vivothan expected from theirin vitrotarget residence time
Vauquelin, G. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2010.512037 · Cited by 98
Designing transient binding drugs: A new concept for drug discovery
Ohlson, S. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.02.001 · Cited by 93
Glycogen Synthase Kinase 3 Is a Potential Drug Target for African Trypanosomiasis Therapy
Ojo, K. K., Gillespie, J. R., Riechers, A. J., Napuli, A. J., Verlinde, C. L. M. J., C, F. S. B. A., Gelb, M. H., Domostoj, M. M., Wells, S. J., Scheer, A., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00364-08 · Cited by 102
High spin cobalt(II) as a probe for the investigation of metalloproteins.
Bertini, I., & Luchinat, C. (1984) · PubMed · Cited by 93
RNA –ligand molecular docking: Advances and challenges
Zhou, Y., Jiang, Y., & Chen, S. (2021) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1571 · Cited by 110
The Role of Fluorine in Glycomimetic Drug Design
Hevey, R. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202003135 · Cited by 95
Chen, X., Huang, X., Ma, Q., Kuzmič, P., Zhou, B., Zhang, S., Chen, J., Xu, J., Liu, B., Jiang, H., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01618-9 · Cited by 100
Modeling covalent-modifier drugs.
Awoonor-Williams, E., Walsh, A. G., & Rowley, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2017.05.009 · Cited by 90
Unexpected Off-Targets and Paradoxical Pathway Activation by Kinase Inhibitors
Hantschel, O. D. (2014) · ACS Chemical Biology · doi:10.1021/cb500886n · Cited by 93
Binding Kinetics Survey of the Drugged Kinome
Georgi, V., Schiele, F., Berger, B., Steffen, A., Zapata, P. A. M., Briem, H., Menz, S., Preuße, C., Vasta, J. D., Robers, M. B., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08048 · Cited by 95
Rocha, J., Almeida, L., Falcão, A. C., Palma, P. N., Loureiro, A. I., Pinto, R. M., Bonifácio, M. J., Wright, L. C., Nunes, T., & Soares-da-Silva, P. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12081 · Cited by 89
Almeida, L., Rocha, J., Falcão, A. C., Palma, P. N., Loureiro, A. I., Pinto, R. M., Bonifácio, M. J., Wright, L. C., Nunes, T., & Soares-da-Silva, P. (2012) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0024-7 · Cited by 88
Molecular Design, Synthesis and Trypanocidal Activity of Dipeptidyl Nitriles as Cruzain Inhibitors
Avelar, L. A. A., Reyes, C. D. C., de Albuquerque, S., Fernandes, W. B., Gonçalez, C., Kenny, P. W., Leitão, A., McKerrow, J. H., Montanari, C. A., Orozco, E. V. M., et al. (2015) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003916 · Cited by 87
Drug–Target Association Kinetics in Drug Discovery
IJzerman, A. P., & Guo, D. M. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.04.004 · Cited by 90
The need for mathematical modelling of spatial drug distribution within the brain
Vendel, E., Rottschäfer, V., & de Lange, E. C. M. (2019) · Fluids and Barriers of the CNS · doi:10.1186/s12987-019-0133-x · Cited by 91
Zhang, R., & Monsma, F. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2010.520700 · Cited by 87
Yang, J., Wang, X., Fuh, G., Yu, L., Wakshull, E., Khosraviani, M., Day, E. S., Demeule, B., Liu, J., Shire, S. J., et al. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500160v · Cited by 89
Ligands, their receptors and … plasma membranes
Vauquelin, G., & Packeu, A. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.07.022 · Cited by 101
Murray, J. B., Roughley, S. D., Matassova, N., & Brough, P. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401848a · Cited by 86
The importance of binding kinetics and drug–target residence time in pharmacology
Knockenhauer, K. E., & Copeland, R. A. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16104 · Cited by 94
Self-citationSimard, J. R., Pawar, V., Aust, B., Wolf, A., Rabiller, M., Wulfert, S., Robubi, A., Klüter, S., Ottmann, C., & Rauh, D. (2009) · Journal of the American Chemical Society · doi:10.1021/ja907795q · Cited by 94
Zhai, X., Ward, R. A., Doig, P., & Argyrou, A. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00104 · Cited by 87
Metadata
- Authors
- Copeland, R. A., Pompliano, D. L., & Meek, T. D.
- Affiliations
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Copeland, Robert A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-08-04
- Volume
- 5
- Issue
- 9
- Pages
- 730-739
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2016408686
- Semantic Scholar
- 362824beb2008831aa65b4eb774e5c8703ff9c71
- Cited by
- 1,464
- References
- 46
- Citations by year
- 2026: 83 · 2025: 64 · 2024: 78 · 2023: 79 · 2022: 81 · 2021: 76 · 2020: 83 · 2019: 88 · 2018: 102 · 2017: 104 · 2016: 96 · 2015: 120 · 2014: 74 · 2013: 88 · 2012: 65
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
- Keywords
- drug-target residence time, lead optimization, drug selectivity, drug-target binding, binding affinity
- MeSH terms
- Binding, Competitive, Pharmaceutical Preparations, Humans, Kinetics, Ligands, Technology, Pharmaceutical, Drug Design, Drug Delivery Systems, Macromolecular Substances
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.